Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 07, 2026 07:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting

LONDON and NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...
April 07, 2026 01:00 ET | Source: Sanofi Winthrop Industrie

Communiqué de presse: Le lunsekimig de Sanofi a atteint les critères d’évaluation principal et secondaires clés dans les études respiratoires de phase 2 dans l’asthme et la rhinosinusite chronique avec polypose nasale

Des études de phase 2 sur le lunsekimig ont atteint les critères d’évaluation principaux et secondaires clés dans deux maladies respiratoires
April 07, 2026 01:00 ET | Source: Sanofi Winthrop Industrie

Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP

Phase 2 studies of lunsekimig, a novel bispecific nanobody, met primary and key secondary endpoints in two chronic respiratory conditions.
April 06, 2026 09:00 ET | Source: Flare Therapeutics Inc.

Flare Therapeutics Announces Three Upcoming Poster Presentations at AACR Annual Meeting 2026

CAMBRIDGE, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for...
April 06, 2026 09:00 ET | Source: Oncolytics Biotech, Inc.

Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer

SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, an...
April 06, 2026 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of Directors

BOSTON, April 06, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment...
April 06, 2026 08:00 ET | Source: Tenvie Therapeutics, Inc.

Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV262, a Fully CNS-Penetrant NLRP3 Inhibitor

First candidate from Tenvie’s product engine to enter clinical developmentPhase 1 first-in-human study to evaluate single and multiple ascending doses of TNV262 in healthy volunteers and persons with...
April 06, 2026 07:30 ET | Source: Medicus Pharma Ltd

Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention

PHILADELPHIA, April 06, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development...
April 03, 2026 17:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

BEDMINSTER, N.J., April 03, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on April 2, 2026, it received a notice (the “Notice”)...
April 03, 2026 08:00 ET | Source: MBX Biosciences, Inc.

MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CARMEL, Ind., April 03, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel...